# Artificial Intelligence In Pharmaceutical Market > Artificial Intelligence In Pharmaceutical Market Research Report: Size, Share, Trend Analysis By Technology (Machine Learning, Natural Language Processing, Computer Vision, Other Technologies), By Applications (Drug Discovery and Development, Clinical Trials, Manufacturing and Supply Chain, Marketing and Sales, Other Applications), By Deployment Model (Cloud-Based, On-Premise, Hybrid), By End-User (Pharmaceutical Companies, Biotechnology Companies, Academic and Research Institutions, Healthcare Providers) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025-2035 - **CAGR:** 19.43% - **2024:** $ 1.49 Billion - **2025:** $ 1.78 Billion - **2035:** $ 10.51 Billion - **Key Players:** IBM, Microsoft, Google, Amazon, Oracle, Sanofi, Aventis, Bayer, AstraZeneca, NVIDIA, Roche, Pfizer, Novartis **Report ID:** MRFR/HC/25130-HCR · **Pages:** 100 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** July 16, 2026 **URL:** https://www.marketresearchfuture.com/reports/artificial-intelligence-in-pharmaceutical-market-26792 --- ## Market Summary ## **Artificial Intelligence In Pharmaceutical Market Overview** As per MRFR analysis, the Artificial Intelligence In Pharmaceutical Market Size was estimated at 1.21 (USD Billion) in 2023. The Artificial Intelligence In Pharmaceutical Market Industry is expected to grow from 1.49 (USD Billion) in 2024 to 7.36 (USD Billion) by 2032. The Market CAGR (growth rate) is expected to be around 19.43% during the forecast period (2024 - 2032). Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Artificial Intelligence In Pharmaceutical Market Drivers** ### **Rising Prevalence of Chronic Diseases** The increasing prevalence of chronic diseases such as cancer, cardiovascular diseases, and diabetes is a major driver of Artificial Intelligence In Pharmaceutical Market Industry. These diseases require complex and long-term treatments, which can be facilitated by AI-powered tools. AI algorithms can analyze vast amounts of patient data to identify patterns and predict disease progression, enabling personalized treatment plans and early detection.This has led to a growing demand for AI-based solutions in the pharmaceutical industry as companies seek to develop more effective and efficient treatments for chronic diseases. ### **Advancements in AI Technology** The development of AI technology is yet another factor that is bound to encourage further growth of the Global Artificial Intelligence In the Pharmaceutical Market Industry. The algorithms are becoming ever more advanced as efforts in the field are funded by massive resources, and computing power also increases exponentially. This allows even the newest models of AI systems to tackle new unknown tasks and problems with great ease and high precision. This, in turn, unlocks new possibilities in the three main areas in which AI is applied – namely, drug discovery, clinical research, and manufacturing.Now, AI is extensively used in each of these fields to analyze the provided data and solve related problems to, for example, determine new drug targets, predict the safety and effectiveness of new drugs, help optimize current production processes, and more. ### **Government Support and Funding** Designed to deliver a superior healthcare experience, artificial intelligence technologies are revolutionizing and overhauling the existing realities of people’s well-being. As such, an increasing number of governments across the globe have started to realize the potential of AI to trigger changes in the realm of healthcare and support patients in maintaining a better state of health. With the demand for AI innovations and, therefore, the opportunities for the enhancement of AI in the pharmaceutical sector with the help of government contributions are becoming more pronounced.As a result, companies and entrepreneurs involved in the creation of AI-driven applications and devices will be granted more support in the form of grants and tax incentives. Hence, government support is bound to have a considerable impact on the development of Global Artificial Intelligence In the Pharmaceutical Market Industry. ## **Artificial Intelligence In Pharmaceutical Market Key Players And Competitive Insights** Major players in Artificial Intelligence In the Pharmaceutical Market industry are continuously competing to enhance their product lines and services to stay ahead of the competition. Leading Artificial Intelligence In Pharmaceutical Market players are expanding their footprints by expanding their presence in new regions and collaborating with other companies. Artificial Intelligence In Pharmaceutical Market development is primarily focused on R&D activities and strategic partnerships. The Artificial Intelligence In Pharmaceutical Market Competitive Landscape is fragmented, with a number of small and medium-sized players competing for a share of the market.  Key players in artificial intelligence in the Pharmaceutical Market include IBM, Microsoft, Google, Amazon, and Oracle. These companies are investing heavily in R&D to develop new and innovative Artificial Intelligence In Pharmaceutical Market products and services. They are also forming partnerships with other companies to expand their reach and gain access to new markets.IBM is a leading provider of Artificial Intelligence In Pharmaceutical Market products and services. The company offers a wide range of solutions, including software, hardware, and services. IBM's Watson AI platform is a key component of its Artificial Intelligence In Pharmaceutical Market offerings. Watson is a cognitive computing platform that can be used to develop a variety of applications, including those for drug discovery, clinical trials, and patient management. Microsoft is another major player in artificial intelligence in the Pharmaceutical Market.  The company offers a range of products and services, including the Azure AI platform. Azure AI is a cloud-based platform that provides developers with a variety of tools and services for developing and deploying AI applications. Microsoft is also working with a number of pharmaceutical companies to develop new AI-based solutions for the industry.Google is a leading provider of cloud-based services. The company offers a range of products and services that can be used to develop and deploy AI applications. Google Cloud AI is a cloud-based platform that provides developers with a variety of tools and services for developing and deploying AI applications. Google is also working with a number of pharmaceutical companies to develop new AI-based solutions for the industry. Amazon is a leading provider of cloud-based services.  The company offers a range of products and services that can be used to develop and deploy AI applications. Amazon Web Services (AWS) is a cloud-based platform that provides developers with a variety of tools and services for developing and deploying AI applications. Amazon is also working with a number of pharmaceutical companies to develop new AI-based solutions for the industry. Oracle is a leading provider of software and services. The company offers a range of products and services that can be used to develop and deploy AI applications. Oracle's AI platform is a key component of its Artificial Intelligence In Pharmaceutical Market offerings. Oracle's AI platform provides developers with a variety of tools and services for developing and deploying AI applications. Oracle is also working with a number of pharmaceutical companies to develop new AI-based solutions for the industry. ### **Key Companies in the Artificial Intelligence In Pharmaceutical Market Include** - Sanofi Aventis - **[Microsoft](https://www.microsoft.com/en-us/industry/healthcare/resources/pharma-medtech-drug-discovery)** - Bayer - Google - IBM - AstraZeneca - NVIDIA - Amazon - Roche - Pfizer - Novartis ### **Key Artificial Intelligence In Pharmaceutical Market Trends Highlighted** Artificial Intelligence (AI) in the Pharmaceutical Market is on a transformative trajectory, driven by advancements in AI capabilities and growing demand for personalized and efficient drug discovery and development processes. Key market drivers include the rising prevalence of chronic diseases, the need for faster and more accurate drug development, and the ability of AI to analyze vast amounts of data for better decision-making. Opportunities in this market lie in the exploration of AI for personalized medicine, predictive analytics, and drug repurposing. Recent trends include the increasing adoption of AI-powered virtual assistants and chatbots, the integration of AI into drug manufacturing, and the development of AI-based tools for clinical trial management. ## **Artificial Intelligence In Pharmaceutical Market Segment Insights** ### **Artificial Intelligence In Pharmaceutical Market Technology Insights** The Artificial Intelligence In Pharmaceutical Market is segmented by Technology into Machine Learning, Natural Language Processing, Computer Vision, and Other Technologies. Machine Learning is the largest segment of the Artificial Intelligence In Pharmaceutical Market and is expected to grow at a CAGR of 28.5% from 2023 to 2032. Machine learning algorithms are used to identify patterns and trends in data, which can be used to improve drug discovery, clinical trials, and drug manufacturing. Natural Language Processing (NLP) is another important segment of the Artificial Intelligence In Pharmaceutical Market and is expected to grow at a CAGR of 27.3% from 2023 to 2032.NLP algorithms can be used to extract insights from unstructured data, such as medical records and scientific literature. This information can be used to improve drug development and clinical trials. Computer Vision is a rapidly growing segment of the Artificial Intelligence In Pharmaceutical Market and is expected to grow at a CAGR of 29.1% from 2023 to 2032.  Computer vision algorithms can be used to analyze images and videos, which can be used to improve drug discovery, clinical trials, and drug manufacturing. Other Technologies in the Artificial Intelligence In Pharmaceutical Market include robotics, blockchain, and augmented reality.This growth is being driven by the increasing adoption of AI technologies in the pharmaceutical industry. AI technologies are being used to improve drug discovery, clinical trials, drug manufacturing, and marketing. Source: Primary Research, Secondary Research, MRFR Database and Analyst Review ### **Artificial Intelligence In Pharmaceutical Market Application Insights** The application segment is a crucial aspect of the Global Artificial Intelligence In the Pharmaceutical Market, driving market growth and innovation. Drug Discovery and Development holds a significant share, leveraging AI's ability to analyze vast datasets, accelerate drug discovery, and optimize clinical trials. Clinical Trials are another key segment where AI enhances efficiency and accuracy in patient recruitment, data collection, and analysis. Manufacturing and Supply Chain applications utilize AI for optimizing production processes, predicting demand, and minimizing waste.Marketing and Sales leverage AI's capabilities in personalized marketing, targeting, and customer relationship management. Other Applications encompass a wide range of AI use cases, such as regulatory compliance, patient safety monitoring, and healthcare research. The Artificial Intelligence In Pharmaceutical Market segmentation provides valuable insights into the specific applications driving market growth and helps stakeholders make informed decisions to capture market opportunities. ### **Artificial Intelligence In Pharmaceutical Market Deployment Model Insights** The deployment model segment of the Artificial Intelligence In Pharmaceutical Market is segmented into cloud-based, on-premise, and hybrid. Among these, the cloud-based segment is expected to hold the largest market share during the forecast period. The growing adoption of cloud-based solutions by pharmaceutical companies due to their scalability, cost-effectiveness, and flexibility is driving the growth of this segment. The on-premise segment is also expected to witness significant growth due to the need for data security and control among pharmaceutical companies.The hybrid cloud segment, which combines the benefits of both cloud-based and on-premise deployment models, is also expected to gain traction in the coming years.  The Artificial Intelligence In Pharmaceutical Market is expected to reach USD 7.36 billion by 2032, exhibiting a CAGR of 19.43% during the forecast period. The increasing adoption of AI in drug discovery, clinical trials, and manufacturing is driving the growth of the market. AI-powered solutions are helping pharmaceutical companies improve the efficiency and accuracy of their operations, which is leading to cost savings and improved patient outcomes. ### **Artificial Intelligence In Pharmaceutical Market End-User Insights** The End-user segment of the Global Artificial Intelligence In the Pharmaceutical Market plays a pivotal role in shaping industry dynamics. Pharmaceutical Companies, Biotechnology Companies, Academic and Research Institutions, Healthcare Providers, and Other End-Users constitute the primary end-user groups. Pharmaceutical Companies are expected to remain dominant, accounting for a significant share of the market in 2023 and beyond. Their focus on leveraging AI to enhance drug discovery, clinical trials, and manufacturing processes drives this dominance.Biotechnology Companies are also investing heavily in AI to accelerate drug development and improve therapeutic outcomes.  Academic and Research Institutions contribute to the market by conducting groundbreaking research and developing novel AI algorithms for pharmaceutical applications. Healthcare Providers utilize AI to enhance patient care through personalized treatments and improved diagnostics. Other End-Users, including contract research organizations and government agencies, further contribute to the market's growth. The increasing adoption of AI in drug development, clinical trials, and healthcare delivery is expected to drive substantial growth in the End-User segment of the Global Artificial Intelligence In the Pharmaceutical Market in the coming years. ### **Artificial Intelligence In Pharmaceutical Market Data Type Insights** The Artificial Intelligence In Pharmaceutical Market is segmented by Data Type into Structured Data, Unstructured Data, and Both Structured and Unstructured Data. Structured Data accounted for the largest market share in 2023 and is expected to continue to dominate the market throughout the forecast period. Structured data is well-organized and easy to analyze, making it ideal for use in AI applications such as predictive modeling and machine learning. Unstructured Data is growing at a rapid pace and is expected to account for a significant share of the market by 2032.Unstructured data includes text, images, and videos, which can be difficult to analyze but can contain valuable insights.  AI applications such as natural language processing and computer vision are becoming increasingly sophisticated at analyzing unstructured data, which is driving the growth of this segment. Both Structured and Unstructured Data are also expected to grow at a healthy pace in the coming years. This segment includes applications that use a combination of structured and unstructured data to improve their performance. The growth of the market is being driven by the increasing adoption of AI in the pharmaceutical industry, as well as the growing availability of data and the development of new AI algorithms. ### **Artificial Intelligence In Pharmaceutical Market Regional Insights** The Artificial Intelligence In Pharmaceutical Market is segmented into North America, Europe, APAC, South America, and MEA. North America held the largest market share in 2023 and is expected to maintain its dominance throughout the forecast period. The growth of the regional market can be attributed to the presence of a large number of pharmaceutical and biotechnology companies in the region, as well as the increasing adoption of AI technologies in drug discovery and development. Europe is the second-largest market for AI in pharmaceuticals and is expected to grow at a significant rate in the coming years.The growth of the regional market can be attributed to the increasing investment in AI research and development by pharmaceutical companies in the region, as well as the supportive regulatory environment.  APAC is the third-largest market for AI in pharmaceuticals and is expected to grow at the fastest rate in the coming years. The growth of the regional market can be attributed to the increasing adoption of AI technologies in drug discovery and development by pharmaceutical companies in the region, as well as the growing demand for personalized medicine.South America and MEA are expected to grow at a moderate rate in the coming years. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## Artificial Intelligence In Pharmaceutical Market Industry Developments - **Q2 2024: Sanofi, Formation Bio and OpenAI partner to build AI-powered software for drug development** Sanofi announced a partnership with Formation Bio and OpenAI to develop custom AI software aimed at accelerating drug development, marking a significant collaboration between a major pharmaceutical company and leading AI technology firms. - **Q2 2024: AstraZeneca Invests in AI Startup Absci to Accelerate Drug Discovery** AstraZeneca made a strategic investment in Absci, an AI-driven drug discovery startup, to leverage Absci’s generative AI platform for designing new biologic drug candidates. - **Q2 2024: Insilico Medicine Announces $80 Million Series D Funding to Advance AI-Driven Drug Discovery** Insilico Medicine raised $80 million in Series D funding to further develop its end-to-end AI drug discovery platform and expand its pipeline of novel therapeutics. - **Q3 2024: Pfizer and Tempus Announce Strategic Collaboration to Leverage AI for Oncology Drug Development** Pfizer and Tempus entered a strategic collaboration to use Tempus’ AI and data analytics platform to accelerate the development of new oncology therapies. - **Q2 2024: Exscientia and Merck KGaA Sign Multi-Year AI Drug Discovery Partnership** Exscientia and Merck KGaA signed a multi-year partnership to use Exscientia’s AI platform for the discovery of novel small molecule drug candidates across multiple therapeutic areas. - **Q1 2025: Recursion Pharmaceuticals Announces FDA Clearance of IND Application for AI-Designed Drug** Recursion Pharmaceuticals received FDA clearance for its Investigational New Drug (IND) application for a novel therapy designed using its proprietary AI platform. - **Q2 2025: Bayer Launches AI Innovation Lab for Pharmaceutical R&D in Berlin** Bayer opened a new AI innovation lab in Berlin dedicated to accelerating pharmaceutical research and development through advanced machine learning and data analytics. - **Q2 2024: BenchSci Raises $95 Million Series D to Expand AI-Driven Preclinical R&D Platform** BenchSci secured $95 million in Series D funding to scale its AI-powered platform that accelerates preclinical research and drug discovery for pharmaceutical companies. - **Q3 2024: GSK and PathAI Announce Partnership to Advance AI-Powered Biomarker Discovery** GSK and PathAI formed a partnership to use PathAI’s machine learning technology for biomarker discovery and patient stratification in clinical trials. - **Q1 2025: Novartis Appoints Chief AI Officer to Lead Digital Transformation in Drug Development** Novartis appointed its first Chief AI Officer to oversee the integration of artificial intelligence across its drug development and clinical operations. - **Q2 2025: Eli Lilly Acquires AI Drug Discovery Startup Cyclica for $250 Million** Eli Lilly acquired Cyclica, a Toronto-based AI drug discovery company, to enhance its capabilities in computational drug design and accelerate its R&D pipeline. - **Q2 2024: Roche and Genentech Launch AI-Driven Platform for Personalized Medicine** Roche and Genentech launched a new AI-powered platform designed to support personalized medicine initiatives by integrating genomic, clinical, and real-world data. ## **Artificial Intelligence In Pharmaceutical Market Segmentation Insights** ### **Artificial Intelligence In Pharmaceutical Market Technology Outlook** - Machine Learning - Natural Language Processing - Computer Vision - Other Technologies ### **Artificial Intelligence In Pharmaceutical Market Application Outlook** - Drug Discovery and Development - Clinical Trials - Manufacturing and Supply Chain - Marketing and Sales - Other Applications ### **Artificial Intelligence In Pharmaceutical Market Deployment Model Outlook** - Cloud-Based - On-Premise - Hybrid ### **Artificial Intelligence In Pharmaceutical Market End-User Outlook** - Pharmaceutical Companies - Biotechnology Companies - Academic and Research Institutions - Healthcare Providers - Other End-Users ### **Artificial Intelligence In Pharmaceutical Market Data Type Outlook** - Structured Data - Unstructured Data - Both Structured and Unstructured Data ### **Artificial Intelligence In Pharmaceutical Market Regional Outlook** - North America - Europe - South America - Asia Pacific - Middle East and Africa ## Market Drivers ### Rising Demand for Drug Discovery The Global Artificial Intelligence In Pharmaceutical Market Industry experiences a notable surge in demand for drug discovery solutions. AI technologies streamline the drug development process, significantly reducing time and costs associated with traditional methods. For instance, AI can analyze vast datasets to identify potential drug candidates, which accelerates the initial phases of research. As of 2024, the market is valued at approximately 1.49 USD Billion, reflecting the growing reliance on AI for efficient drug discovery. This trend is expected to continue, with projections indicating a market expansion to 12.5 USD Billion by 2035, driven by a compound annual growth rate of 21.37% from 2025 to 2035. ## Future Outlook The Artificial Intelligence in Pharmaceutical Market is poised for growth at 19.43% CAGR from 2024 to 2032, driven by advancements in drug discovery, personalized medicine, and operational efficiencies. **New opportunities:** - Develop AI-driven platforms for predictive analytics in clinical trials. Invest in AI solutions for drug repurposing and optimization. Create partnerships with tech firms to enhance AI capabilities in pharmaceutical research. By 2035, the market is expected to reach unprecedented levels, reflecting robust innovation and strategic partnerships. ## Segment Insights ### By Technology: Machine Learning (Largest) vs. Natural Language Processing (Fastest-Growing) Machine Learning dominates the Artificial Intelligence in Pharmaceutical Market, providing robust solutions that streamline drug discovery, optimize clinical trials, and improve patient outcomes. Its ability to analyze large datasets enhances operational efficiency and decision-making across pharmaceutical research and development. Meanwhile, Natural Language Processing is rapidly emerging as a key growth area by enabling the analysis of unstructured data such as clinical notes and research publications, supporting informed decision-making and personalized medicine initiatives. The growing need for automation, predictive analytics, and efficient data interpretation continues to strengthen the adoption of both technologies, with Machine Learning maintaining its leadership position while Natural Language Processing gains increasing momentum. ### By Application: Drug Discovery and Development (Largest) vs. Clinical Trials (Fastest-Growing) Drug Discovery and Development represents the largest application segment in the Artificial Intelligence in Pharmaceutical Market, driven by AI's ability to accelerate candidate identification, reduce development timelines, and improve research efficiency. Clinical Trials are emerging as the fastest-growing application, supported by AI-powered patient recruitment, real-time data analysis, and adaptive trial management. As pharmaceutical companies increasingly invest in AI-driven research, both segments continue to benefit from improved operational efficiency, enhanced decision-making, and faster development of innovative therapies. ### By Deployment Model: Cloud-Based (Largest) vs. On-Premise (Fastest-Growing) Cloud-Based deployment holds the largest share in the Artificial Intelligence in Pharmaceutical Market due to its scalability, flexibility, and cost-effectiveness, making it the preferred choice for pharmaceutical organizations implementing AI solutions. On-Premise deployment is witnessing rapid growth as companies prioritize greater control over sensitive healthcare data, regulatory compliance, and data security. While cloud platforms continue to support collaboration and large-scale analytics, on-premise solutions are increasingly adopted by organizations requiring enhanced infrastructure control and privacy protection. ### By End-User: Pharmaceutical Companies (Largest) vs. Biotechnology Companies (Fastest-Growing) Pharmaceutical Companies account for the largest share of the market, leveraging AI technologies across drug discovery, clinical development, and personalized medicine initiatives. Biotechnology Companies are rapidly expanding their AI adoption to accelerate compound screening, improve research efficiency, and develop innovative therapeutic solutions. Increased investments, technological advancements, and the growing need for faster drug development continue to support the expansion of both end-user segments. ### By Data Type: Structured Data (Largest) vs. Unstructured Data (Fastest-Growing) Structured Data remains the dominant data type in the Artificial Intelligence in Pharmaceutical Market due to its standardized format, enabling efficient processing, predictive analytics, and integration into AI algorithms. Unstructured Data is gaining significant traction as advances in machine learning and natural language processing enable pharmaceutical companies to extract valuable insights from clinical notes, medical images, research publications, and other text-based information. The increasing utilization of diverse data sources is expected to further strengthen AI-driven innovation and personalized medicine capabilities. ## Competitive Benchmarking Major players in Artificial Intelligence In the Pharmaceutical Market industry are continuously competing to enhance their product lines and services to stay ahead of the competition. Leading Artificial Intelligence In Pharmaceutical Market players are expanding their footprints by expanding their presence in new regions and collaborating with other companies. Artificial Intelligence In Pharmaceutical Market development is primarily focused on R&D activities and strategic partnerships. The Artificial Intelligence In Pharmaceutical Market Competitive Landscape is fragmented, with a number of small and medium-sized players competing for a share of the market. Key players in [artificial intelligence](https://www.marketresearchfuture.com/reports/artificial-intelligence-market-1139) in the Pharmaceutical Market include IBM, Microsoft, Google, Amazon, and Oracle. These companies are investing heavily in R&D to develop new and innovative Artificial Intelligence In Pharmaceutical Market products and services. They are also forming partnerships with other companies to expand their reach and gain access to new markets.IBM is a leading provider of Artificial Intelligence In Pharmaceutical Market products and services. The company offers a wide range of solutions, including software, hardware, and services. IBM's Watson AI platform is a key component of its Artificial Intelligence In Pharmaceutical Market offerings.Watson is a cognitive computing platform that can be used to develop a variety of applications, including those for drug discovery, clinical trials, and patient management. Microsoft is another major player in artificial intelligence in the Pharmaceutical Market. The company offers a range of products and services, including the Azure AI platform. Azure AI is a cloud-based platform that provides developers with a variety of tools and services for developing and deploying AI applications. Microsoft is also working with a number of pharmaceutical companies to develop new AI-based solutions for the industry.Google is a leading provider of cloud-based services. The company offers a range of products and services that can be used to develop and deploy AI applications.Google Cloud AI is a cloud-based platform that provides developers with a variety of tools and services for developing and deploying AI applications. Google is also working with a number of pharmaceutical companies to develop new AI-based solutions for the industry. Amazon is a leading provider of cloud-based services. The company offers a range of products and services that can be used to develop and deploy AI applications. Amazon Web Services (AWS) is a cloud-based platform that provides developers with a variety of tools and services for developing and deploying AI applications. Amazon is also working with a number of pharmaceutical companies to develop new AI-based solutions for the industry. Oracle is a leading provider of software and services. The company offers a range of products and services that can be used to develop and deploy AI applications.Oracle's AI platform is a key component of its Artificial Intelligence In Pharmaceutical Market offerings. Oracle's AI platform provides developers with a variety of tools and services for developing and deploying AI applications. Oracle is also working with a number of pharmaceutical companies to develop new AI-based solutions for the industry. ## Recent News & Developments - **Q2 2024: Sanofi, Formation Bio and OpenAI partner to build AI-powered software for drug development** Sanofi announced a partnership with Formation Bio and OpenAI to develop custom AI software aimed at accelerating drug development, marking a significant collaboration between a major pharmaceutical company and leading AI technology firms. - **Q2 2024: AstraZeneca Invests in AI Startup Absci to Accelerate Drug Discovery** AstraZeneca made a strategic investment in Absci, an AI-driven drug discovery startup, to leverage Absci’s generative AI platform for designing new biologic drug candidates. - **Q2 2024: Insilico Medicine Announces $80 Million Series D Funding to Advance AI-Driven Drug Discovery** Insilico Medicine raised $80 million in Series D funding to further develop its end-to-end AI drug discovery platform and expand its pipeline of novel therapeutics. - **Q3 2024: Pfizer and Tempus Announce Strategic Collaboration to Leverage AI for Oncology Drug Development** Pfizer and Tempus entered a strategic collaboration to use Tempus’ AI and data analytics platform to accelerate the development of new oncology therapies. - **Q2 2024: Exscientia and Merck KGaA Sign Multi-Year AI Drug Discovery Partnership** Exscientia and Merck KGaA signed a multi-year partnership to use Exscientia’s AI platform for the discovery of novel small molecule drug candidates across multiple therapeutic areas. - **Q1 2025: Recursion Pharmaceuticals Announces FDA Clearance of IND Application for AI-Designed Drug** Recursion Pharmaceuticals received FDA clearance for its Investigational New Drug (IND) application for a novel therapy designed using its proprietary AI platform. - **Q2 2025: Bayer Launches AI Innovation Lab for Pharmaceutical R&D in Berlin** Bayer opened a new AI innovation lab in Berlin dedicated to accelerating pharmaceutical research and development through advanced machine learning and data analytics. - **Q2 2024: BenchSci Raises $95 Million Series D to Expand AI-Driven Preclinical R&D Platform** BenchSci secured $95 million in Series D funding to scale its AI-powered platform that accelerates preclinical research and drug discovery for pharmaceutical companies. - **Q3 2024: GSK and PathAI Announce Partnership to Advance AI-Powered Biomarker Discovery** GSK and PathAI formed a partnership to use PathAI’s machine learning technology for biomarker discovery and patient stratification in clinical trials. - **Q1 2025: Novartis Appoints Chief AI Officer to Lead Digital Transformation in Drug Development** Novartis appointed its first Chief AI Officer to oversee the integration of artificial intelligence across its drug development and clinical operations. - **Q2 2025: Eli Lilly Acquires AI Drug Discovery Startup Cyclica for $250 Million** Eli Lilly acquired Cyclica, a Toronto-based AI drug discovery company, to enhance its capabilities in computational drug design and accelerate its R&D pipeline. - **Q2 2024: Roche and Genentech Launch AI-Driven Platform for Personalized Medicine** Roche and Genentech launched a new AI-powered platform designed to support personalized medicine initiatives by integrating genomic, clinical, and real-world data. ## Report Scope | Report Attribute/Metric | Details | | --- | --- | | Market Size 2024 | 1.49 (USD Billion) | | Market Size 2035 | 10.51 (USD Billion) | | Compound Annual Growth Rate (CAGR) | 19.43% (2025 - 2035) | | Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | Base Year | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2018-2022 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Sanofi Aventis, Microsoft, Bayer, Google, IBM, AstraZeneca, NVIDIA, Amazon, Roche, Pfizer, Novartis | | Segments Covered | Technology, Application, Deployment Model, End-User, Data Type, Regional | | Key Market Opportunities | Precision Medicine Drug Discovery Optimization Clinical Trial Management Personalized Treatment Plans Remote Patient Monitoring | | Key Market Dynamics | Growing demand for personalized medicine Increasing adoption of AI in drug discovery Advancements in machine learning and deep learning Government initiatives and funding Strategic partnerships and collaborations. | | Countries Covered | North America, Europe, APAC, South America, MEA | | Market Size 2025 | 1.78 (USD Billion) | ## Frequently Asked Questions **Q: What is the projected growth of the Artificial Intelligence In Pharmaceutical market?** A: The Artificial Intelligence In Pharmaceutical market is the expected increase in total market value of 10.51 USD billion over a defined forecast period 2025–2035. It is driven by factors such as demand trends, technological advances, regulatory changes, and geographic expansion. **Q: What is the size of the Artificial Intelligence In Pharmaceutical market?** A: Artificial Intelligence In Pharmaceutical market size was valued at approximately 1.49 billion USD in 2024. This figure will reach 10.51 billion USD covering all regions (America, Europe, Asia, MEA and ROW), focusing its segments / services / distribution channels till 2035. **Q: What is the CAGR of the Artificial Intelligence In Pharmaceutical market?** A: Artificial Intelligence In Pharmaceutical market is expected to grow at a CAGR of 19.43% between 2025 and 2035. **Q: How much will the Artificial Intelligence In Pharmaceutical market be worth by 2035?** A: Artificial Intelligence In Pharmaceutical market is expected to be worth of 10.51 billion USD, reflecting growth driven by usage, technology and global demands by the end of 2035. **Q: How will the Artificial Intelligence In Pharmaceutical market perform over the next 10 years?** A: Over the next 10 years the Artificial Intelligence In Pharmaceutical market is expected to shift from usd billion 1.49 to 10.51 billion USD, led by adoption of advanced tech, demographic trends, regulatory approvals, with potential headwinds from 2025 to 2035. **Q: What is the regional breakdown of the Artificial Intelligence In Pharmaceutical Market?** A: North America held the largest share of AI in the pharmaceutical market and is expected to maintain its dominance throughout the forecast period. Europe is projected to witness a significant growth rate owing to the increasing adoption of AI in drug discovery and development. **Q: What are the key drivers of the Artificial Intelligence In Pharmaceutical Market?** A: Major factors driving the growth of AI in the pharmaceutical market include the rising demand for personalized medicine, the need for faster and more efficient drug discovery and development processes, and the increasing adoption of AI in clinical trials. **Q: What are the key applications of Artificial Intelligence in the Pharmaceutical Industry?** A: Key applications of AI in the pharmaceutical industry include drug discovery, clinical trials, personalized medicine, and manufacturing. **Q: Who are the major competitors in the Artificial Intelligence In Pharmaceutical Market?** A: Major players operating in the Global AI in the Pharmaceutical Market include IBM, Microsoft, Google, Amazon, and Oracle. **Q: What is the outlook for the Artificial Intelligence In Pharmaceutical Market?** A: The Global AI in Pharmaceutical Market is expected to witness substantial growth over the forecast period, driven by factors such as the increasing adoption of AI in drug discovery and development, the rising demand for personalized medicine, and the growing need for faster and more efficient clinical trials. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/artificial-intelligence-in-pharmaceutical-market-26792*